How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• ROS proto-oncogene 1 (ROS1) rearrangements are found in 1-2% of lung adenocarcinomas and other solid tumors, defining a distinct NSCLC subgroup.
• Current guidelines recommend screening for ROS1 rearrangements in advanced non-squamous NSCLC and certain squamous lung cancer patients.
• Crizotinib is a recommended treatment for ROS1-positive NSCLC, but resistance often develops due to secondary mutations or central nervous system (CNS) failure.

Purpose of the Study:

• To review the landscape of ROS1 rearrangements in non-small cell lung cancer.
• To discuss the efficacy and challenges of crizotinib treatment.
• To highlight the potential of novel, CNS-penetrant ROS1 inhibitors, such as entrectinib, in managing ROS1-positive NSCLC.

Main Methods:

• Review of clinical trial data and scientific literature concerning ROS1 rearrangements in NSCLC.
• Analysis of treatment outcomes for crizotinib and emerging ROS1 inhibitors.
• Evaluation of the pharmacokinetic properties, including CNS penetration, of novel inhibitors.

Main Results:

• ROS1 rearrangements are associated with specific patient demographics (younger, never-smokers, adenocarcinoma histology).
• Crizotinib demonstrates efficacy but is limited by acquired resistance and CNS progression.
• Second-generation inhibitors, including entrectinib, exhibit potent activity against ROS1 and its resistant mutations, with favorable CNS penetration.

Conclusions:

• Identification and targeted therapy are crucial for ROS1-positive NSCLC.
• Novel ROS1 inhibitors offer improved efficacy and CNS coverage, potentially overcoming resistance mechanisms.
• Ongoing research and clinical trials are essential to establish optimal treatment sequences for ROS1-positive NSCLC.